These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33180848)

  • 1. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
    Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M
    PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.
    Rath T; Billmeier U; Ferrazzi F; Vieth M; Ekici A; Neurath MF; Atreya R
    Front Immunol; 2018; 9():1700. PubMed ID: 30131801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis.
    Wittner M; Schlicker V; Libera J; Bockmann JH; Horvatits T; Seiz O; Kummer S; Manthey CF; Hüfner A; Kantowski M; Rösch T; Degen O; Huber S; Eberhard JM; Schulze Zur Wiesch J
    PLoS One; 2019; 14(7):e0220008. PubMed ID: 31356607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline levels of dynamic CD4
    Allner C; Melde M; Becker E; Fuchs F; Mühl L; Klenske E; Müller L; Morgenstern N; Fietkau K; Hirschmann S; Atreya R; Atreya I; Neurath MF; Zundler S
    BMC Gastroenterol; 2020 Apr; 20(1):103. PubMed ID: 32293299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab-mediated integrin α4β7 blockade does not control HIV-1SF162 rebound after combination antiretroviral therapy interruption in humanized mice.
    Ling L; Wu T; To KKW; Cheung KW; Lui KOL; Niu M; Lam KS; Wang CC; Li J; Wang H; Yuen KY; Chen Z
    AIDS; 2019 Mar; 33(4):F1-F12. PubMed ID: 30829743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes.
    Wyant T; Yang L; Fedyk E
    MAbs; 2013; 5(6):842-50. PubMed ID: 24492340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
    Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
    J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introducing vedolizumab to clinical practice: who, when, and how?
    Bryant RV; Sandborn WJ; Travis SP
    J Crohns Colitis; 2015 Apr; 9(4):356-66. PubMed ID: 25687206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis.
    Veny M; Garrido-Trigo A; Corraliza AM; Masamunt MC; Bassolas-Molina H; Esteller M; Arroyes M; Tristán E; Fernández-Clotet A; Ordás I; Ricart E; Esteve M; Panés J; Salas A
    J Crohns Colitis; 2021 Mar; 15(3):441-452. PubMed ID: 32926095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of αEβ7 integrin suppresses accumulation of CD8
    Zundler S; Schillinger D; Fischer A; Atreya R; López-Posadas R; Watson A; Neufert C; Atreya I; Neurath MF
    Gut; 2017 Nov; 66(11):1936-1948. PubMed ID: 27543429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
    Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
    J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets.
    Becker E; Schweda A; Ullrich KA; Voskens C; Atreya R; Müller TM; Atreya I; Neurath MF; Zundler S
    Clin Transl Gastroenterol; 2022 Jun; 13(6):e00494. PubMed ID: 35575178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
    Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
    Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis.
    Roosenboom B; Wahab PJ; Smids C; Meijer J; Kemperman LGJM; Groenen MJM; van Lochem EG; Horjus Talabur Horje CS
    Inflamm Bowel Dis; 2024 Jun; 30(6):930-938. PubMed ID: 37436917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
    Boden EK; Shows DM; Chiorean MV; Lord JD
    Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy.
    Abreu MT; Davies JM; Quintero MA; Delmas A; Diaz S; Martinez CD; Venables T; Reich A; Crynen G; Deshpande AR; Kerman DH; Damas OM; Fernandez I; Santander AM; Pignac-Kobinger J; Burgueno JF; Sundrud MS
    Inflamm Bowel Dis; 2022 Dec; 28(12):1800-1812. PubMed ID: 35993552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.